Antiplatelet Agent Currently in Shortage
The Food and Drug Administration (FDA) is notifying healthcare professionals about a shortage of the cardiovascular drug Integrilin (eptifibatide injection). As per Merck, the shortage is due to manufacturing delays.
Integrilin, a platelet aggregation inhibitor, is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with acute coronary syndrome (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). It is also indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting.
Limited inventory of the 20mg (10mL vial), 75mg (100mL vial), and 200mg (100mL vial) strengths is available. Inventory will be re-supplied periodically.
For more information visit Merck.com.